Prognostic Factors for Survival in Patients With Cholangiocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-01

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this retrospective study is to determine the survival rates of CCA patients based on different therapeutic approaches. Additionally, we aim to investigate the risk factors associated with poor survival within a cohort of patients treated over a seven-year period across four Danish hospitals. We anticipate that our findings could provide additional evidence for clinical decision-making, improve patient outcomes, and contribute to the knowledge in the field.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients

NCT04415190

Cholangiocarcinoma

UNKNOWN

Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma

NCT06671431

Distal Cholangiocarcinoma Adjuvant Chemotherapy

COMPLETED

Radical Surgery for Advanced Gastric- or GEJ-cancer With Oligometastatic Dissmination to the Liver

NCT06627634

Survival

RECRUITING NA

Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery

NCT01189227

Colorectal Cancer Metastatic Cancer

TERMINATED PHASE3

Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease

NCT07284394

Colorectal Adenocarcinoma Metastatic in the Liver Colorectal Cancer

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND

Cholangiocarcinoma (CCA) is a highly aggressive neoplasia and is considered the second most common primary liver cancer (1). Its global mortality has shown an upward trend over the last two decades (2), with a survival rate of less than 5% at 5 years. The poor prognosis is related to late-stage detection since CCA can be asymptomatic in its early stages (3). In Denmark, the estimated cumulative risk of mortality due to CCA was 0.74 for men (ranking 20th in all of Europe) and 0.34 for women (ranking 6th in Europe) (4).

CCA is anatomically classified into three groups: intrahepatic, perihilar, and distal CCA (1,2). Additionally, CCA can be classified as mass-forming, periductal infiltrating, and intraductal based on tumor location, which may be associated with tumor morphology (3). A precise anatomical classification of CCA in each case is essential for accurately assessing potential complications (1).

The diagnosis, staging, and treatment of CCA can be challenging and are typically performed by a multidisciplinary team (MDT) of specialists. MDT meetings are a common practice in cancer care aimed at improving survival. However, it is important to note that there are currently no standardized recommendations for MDT practices in CCA (2). Recently, authors have made efforts to identify areas of improvement and establish standard guidelines for MDT decisions based on the current practices of specialized European teams with expertise in CCA. According to the recommendations of the European Network for the Study of Cholangiocarcinoma, international guidelines should be utilized for MDT decisions. However, preference for national guidelines should be given (2) Nevertheless, at the moment, there are not in Denmark a national guideline to determine the most optimal treatment for CCA patients based on local statistics.

Hence, the objective of this retrospective study was to determine the survival rates of CCA patients based on different therapeutic approaches. Additionally, we aimed to investigate the risk factors associated with poor survival within a cohort of patients treated over a seven-year period across four Danish hospitals. We anticipate that our findings could provide additional evidence for clinical decision-making, improve patient outcomes, and contribute to the knowledge in the field.

AIMS AND HYPOTHESIS

Aim I Determine the survival rates of CCA patients based on various therapeutic approaches following the MDT decision.

Aim II Determine the risk factors associated with unfavorable overall survival in CCA patients.

Hypothesis Advanced age, male gender, poor performance status, non-operability, lack of tumor resectability, and being treated in a hospital where the MDT decision is made all pose as poor survival risk factors for CCA patients. In contrast, we anticipate a better prognosis for patients undergoing curative treatment (surgery) compared to non-surgical treatments. Finally, our hypothesis suggests that chemotherapy provides a better prognosis than no treatment in CCA patients.

KEY DATA SOURCES

Primary data sources Patients will be identified in the Danish Liver-Biliary Cancer Database and data was retrieved retrospectively from medical records in individual centers. The Danish Data Protection Agency (p-2023-14848) has approved the study.

Inclusion criteria Patients' eligibility for this study is contingent on a diagnosis of CCA confirmed by the MDT from Aalborg Universitetshospital, Aarhus Universitetshospital, Odense Universitetshospital, and Rigshospitalet in Denmark from 2013 to 2020.

Exclusion criteria We will exclude from the analysis all records resulting from more than one intervention (on the same patient). Additionally, all patients whose cholangiocarcinoma diagnosis was canceled following the MDT meeting were also excluded, as well those with inconsistent data regarding date of reference to the MDT.

DEFINITION OF PRIMARY OUTCOMES Overall survival will be defined as the period from the initial diagnosis of the disease to the registered date of death, regardless of the cause. The disease diagnosis will be determined from the date of MDT referral, and the date of death will be based on the information provided in the Danish Civil Registration (CPR) number.

STATISTICAL ANALYSIS Patient baseline characteristics were described using the mean and standard deviation (SD) for continuous data and frequency and percentage for categorical data. Differences between treatment plan groups in variables with a normal distribution were analyzed with an ANOVA test. Non-normally distributed data were analyzed with Kruskal-Wallis test and presented as medians and interquartile ranges. Overall survival was calculated from the date of referral to the MDT to the date of death reported in the Danish Civil Registration (CPR) number. Survival analysis was conducted using the Kaplan-Meier estimator with a 95% confidence interval. The analysis of risk factors associated with CCA patients' survival was performed using univariate Cox regression analysis. Significance was considered when the P-value was \<0.05. All analyses were conducted using SPSS version 29.0.01.1 (171).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholangiocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cholangiocarcinoma

Patients with diagnosis of Cholangiocarcinoma confirmed by MDT

Resection/Ablation of tumor

Intervention Type PROCEDURE

Curative treatment

Palliative chemotherapy

Intervention Type PROCEDURE

Chemotherapeutic medications

Neoadjuvant chemotherapy

Intervention Type PROCEDURE

Chemotherapeutic medications after surgery

Stereotatic radiotherapy

Intervention Type PROCEDURE

Radiotherapy

Best supportive care

Intervention Type PROCEDURE

Symptomatic treatment, non-curative treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Resection/Ablation of tumor

Curative treatment

Intervention Type PROCEDURE

Palliative chemotherapy

Chemotherapeutic medications

Intervention Type PROCEDURE

Neoadjuvant chemotherapy

Chemotherapeutic medications after surgery

Intervention Type PROCEDURE

Stereotatic radiotherapy

Radiotherapy

Intervention Type PROCEDURE

Best supportive care

Symptomatic treatment, non-curative treatment

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Surgery Chemotherapy Adjuvant chemotherapy Radiotherapy Supportive care

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients' eligibility for this study is contingent on a diagnosis of CCA confirmed by the MDT from Aalborg Universitetshospital, Aarhus Universitetshospital, Odense Universitetshospital, and Rigshospitalet in Denmark from 2013 to 2020.

Exclusion Criteria

* We will exclude from the analysis all records with more than one interventions. Additionally, all patients whose cholangiocarcinoma diagnosis was canceled following the MDT meeting will be also excluded, as well those with inconsistent data regarding date of reference to the MDT.

Eligible Sex

ALL

Accepts Healthy Volunteers

No